PMC:7073332 / 31237-32587 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T155","span":{"begin":56,"end":65},"obj":"Body_part"},{"id":"T156","span":{"begin":124,"end":132},"obj":"Body_part"},{"id":"T157","span":{"begin":324,"end":333},"obj":"Body_part"},{"id":"T158","span":{"begin":436,"end":445},"obj":"Body_part"},{"id":"T159","span":{"begin":599,"end":608},"obj":"Body_part"},{"id":"T160","span":{"begin":633,"end":643},"obj":"Body_part"},{"id":"T161","span":{"begin":648,"end":658},"obj":"Body_part"},{"id":"T162","span":{"begin":804,"end":811},"obj":"Body_part"},{"id":"T163","span":{"begin":901,"end":910},"obj":"Body_part"},{"id":"T164","span":{"begin":1039,"end":1048},"obj":"Body_part"},{"id":"T165","span":{"begin":1295,"end":1304},"obj":"Body_part"}],"attributes":[{"id":"A155","pred":"fma_id","subj":"T155","obj":"http://purl.org/sig/ont/fma/fma74644"},{"id":"A156","pred":"fma_id","subj":"T156","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A157","pred":"fma_id","subj":"T157","obj":"http://purl.org/sig/ont/fma/fma74644"},{"id":"A158","pred":"fma_id","subj":"T158","obj":"http://purl.org/sig/ont/fma/fma74644"},{"id":"A159","pred":"fma_id","subj":"T159","obj":"http://purl.org/sig/ont/fma/fma74644"},{"id":"A160","pred":"fma_id","subj":"T160","obj":"http://purl.org/sig/ont/fma/fma62343"},{"id":"A161","pred":"fma_id","subj":"T161","obj":"http://purl.org/sig/ont/fma/fma62343"},{"id":"A162","pred":"fma_id","subj":"T162","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A163","pred":"fma_id","subj":"T163","obj":"http://purl.org/sig/ont/fma/fma74644"},{"id":"A164","pred":"fma_id","subj":"T164","obj":"http://purl.org/sig/ont/fma/fma74644"},{"id":"A165","pred":"fma_id","subj":"T165","obj":"http://purl.org/sig/ont/fma/fma74644"}],"text":"As shown in Fig. 5a, targets of both mercaptopurine and melatonin showed strong network proximity with HCoV-associated host proteins in the human interactome network. Recent in vitro and in vivo studies identified mercaptopurine as a selective inhibitor of both SARS-CoV and MERS-CoV by targeting papain-like protease53,54. Melatonin was reported in potential antiviral infection via its anti-inflammatory and antioxidant effects58–62. Melatonin indirectly regulates ACE2 expression, a key entry receptor involved in viral infection of HCoVs, including 2019-nCoV/SARS-CoV-2 (ref. 33). Specifically, melatonin was reported to inhibit calmodulin and calmodulin interacts with ACE2 by inhibiting shedding of its ectodomain, a key infectious process of SARS-CoV72,73. JUN, also known as c-Jun, is a key host protein involving in HCoV infectious bronchitis virus74. As shown in Fig. 6d, mercaptopurine and melatonin may synergistically block c-Jun signaling by targeting multiple cellular targets. In summary, combination of mercaptopurine and melatonin may offer a potential combination therapy for 2019-nCoV/SARS-CoV-2 by synergistically targeting papain-like protease, ACE2, c-Jun signaling, and anti-inflammatory pathways (Fig. 6d). However, further experimental observations on ACE2 pathways by melatonin in 2019-nCoV/SARS-CoV-2 are highly warranted."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T132","span":{"begin":262,"end":270},"obj":"Disease"},{"id":"T133","span":{"begin":370,"end":379},"obj":"Disease"},{"id":"T134","span":{"begin":517,"end":532},"obj":"Disease"},{"id":"T135","span":{"begin":523,"end":532},"obj":"Disease"},{"id":"T136","span":{"begin":563,"end":571},"obj":"Disease"},{"id":"T137","span":{"begin":727,"end":737},"obj":"Disease"},{"id":"T138","span":{"begin":749,"end":753},"obj":"Disease"},{"id":"T139","span":{"begin":830,"end":840},"obj":"Disease"},{"id":"T140","span":{"begin":841,"end":851},"obj":"Disease"},{"id":"T141","span":{"begin":1105,"end":1113},"obj":"Disease"},{"id":"T142","span":{"begin":1318,"end":1326},"obj":"Disease"}],"attributes":[{"id":"A132","pred":"mondo_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A133","pred":"mondo_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A134","pred":"mondo_id","subj":"T134","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A135","pred":"mondo_id","subj":"T135","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A136","pred":"mondo_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A137","pred":"mondo_id","subj":"T137","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A138","pred":"mondo_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A139","pred":"mondo_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A140","pred":"mondo_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/MONDO_0003781"},{"id":"A141","pred":"mondo_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A142","pred":"mondo_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"As shown in Fig. 5a, targets of both mercaptopurine and melatonin showed strong network proximity with HCoV-associated host proteins in the human interactome network. Recent in vitro and in vivo studies identified mercaptopurine as a selective inhibitor of both SARS-CoV and MERS-CoV by targeting papain-like protease53,54. Melatonin was reported in potential antiviral infection via its anti-inflammatory and antioxidant effects58–62. Melatonin indirectly regulates ACE2 expression, a key entry receptor involved in viral infection of HCoVs, including 2019-nCoV/SARS-CoV-2 (ref. 33). Specifically, melatonin was reported to inhibit calmodulin and calmodulin interacts with ACE2 by inhibiting shedding of its ectodomain, a key infectious process of SARS-CoV72,73. JUN, also known as c-Jun, is a key host protein involving in HCoV infectious bronchitis virus74. As shown in Fig. 6d, mercaptopurine and melatonin may synergistically block c-Jun signaling by targeting multiple cellular targets. In summary, combination of mercaptopurine and melatonin may offer a potential combination therapy for 2019-nCoV/SARS-CoV-2 by synergistically targeting papain-like protease, ACE2, c-Jun signaling, and anti-inflammatory pathways (Fig. 6d). However, further experimental observations on ACE2 pathways by melatonin in 2019-nCoV/SARS-CoV-2 are highly warranted."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T230","span":{"begin":140,"end":145},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T231","span":{"begin":232,"end":233},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T232","span":{"begin":484,"end":485},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T233","span":{"begin":721,"end":722},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T234","span":{"begin":793,"end":794},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T235","span":{"begin":943,"end":952},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T236","span":{"begin":1059,"end":1060},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T237","span":{"begin":1179,"end":1188},"obj":"http://purl.obolibrary.org/obo/SO_0000418"}],"text":"As shown in Fig. 5a, targets of both mercaptopurine and melatonin showed strong network proximity with HCoV-associated host proteins in the human interactome network. Recent in vitro and in vivo studies identified mercaptopurine as a selective inhibitor of both SARS-CoV and MERS-CoV by targeting papain-like protease53,54. Melatonin was reported in potential antiviral infection via its anti-inflammatory and antioxidant effects58–62. Melatonin indirectly regulates ACE2 expression, a key entry receptor involved in viral infection of HCoVs, including 2019-nCoV/SARS-CoV-2 (ref. 33). Specifically, melatonin was reported to inhibit calmodulin and calmodulin interacts with ACE2 by inhibiting shedding of its ectodomain, a key infectious process of SARS-CoV72,73. JUN, also known as c-Jun, is a key host protein involving in HCoV infectious bronchitis virus74. As shown in Fig. 6d, mercaptopurine and melatonin may synergistically block c-Jun signaling by targeting multiple cellular targets. In summary, combination of mercaptopurine and melatonin may offer a potential combination therapy for 2019-nCoV/SARS-CoV-2 by synergistically targeting papain-like protease, ACE2, c-Jun signaling, and anti-inflammatory pathways (Fig. 6d). However, further experimental observations on ACE2 pathways by melatonin in 2019-nCoV/SARS-CoV-2 are highly warranted."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T364","span":{"begin":37,"end":51},"obj":"Chemical"},{"id":"T365","span":{"begin":56,"end":65},"obj":"Chemical"},{"id":"T366","span":{"begin":124,"end":132},"obj":"Chemical"},{"id":"T367","span":{"begin":214,"end":228},"obj":"Chemical"},{"id":"T368","span":{"begin":244,"end":253},"obj":"Chemical"},{"id":"T369","span":{"begin":324,"end":333},"obj":"Chemical"},{"id":"T370","span":{"begin":360,"end":369},"obj":"Chemical"},{"id":"T371","span":{"begin":410,"end":421},"obj":"Chemical"},{"id":"T372","span":{"begin":436,"end":445},"obj":"Chemical"},{"id":"T373","span":{"begin":599,"end":608},"obj":"Chemical"},{"id":"T374","span":{"begin":804,"end":811},"obj":"Chemical"},{"id":"T375","span":{"begin":882,"end":896},"obj":"Chemical"},{"id":"T376","span":{"begin":901,"end":910},"obj":"Chemical"},{"id":"T377","span":{"begin":1020,"end":1034},"obj":"Chemical"},{"id":"T378","span":{"begin":1039,"end":1048},"obj":"Chemical"},{"id":"T379","span":{"begin":1295,"end":1304},"obj":"Chemical"}],"attributes":[{"id":"A364","pred":"chebi_id","subj":"T364","obj":"http://purl.obolibrary.org/obo/CHEBI_50667"},{"id":"A365","pred":"chebi_id","subj":"T365","obj":"http://purl.obolibrary.org/obo/CHEBI_16796"},{"id":"A366","pred":"chebi_id","subj":"T366","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A367","pred":"chebi_id","subj":"T367","obj":"http://purl.obolibrary.org/obo/CHEBI_50667"},{"id":"A368","pred":"chebi_id","subj":"T368","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A369","pred":"chebi_id","subj":"T369","obj":"http://purl.obolibrary.org/obo/CHEBI_16796"},{"id":"A370","pred":"chebi_id","subj":"T370","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A371","pred":"chebi_id","subj":"T371","obj":"http://purl.obolibrary.org/obo/CHEBI_22586"},{"id":"A372","pred":"chebi_id","subj":"T372","obj":"http://purl.obolibrary.org/obo/CHEBI_16796"},{"id":"A373","pred":"chebi_id","subj":"T373","obj":"http://purl.obolibrary.org/obo/CHEBI_16796"},{"id":"A374","pred":"chebi_id","subj":"T374","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A375","pred":"chebi_id","subj":"T375","obj":"http://purl.obolibrary.org/obo/CHEBI_50667"},{"id":"A376","pred":"chebi_id","subj":"T376","obj":"http://purl.obolibrary.org/obo/CHEBI_16796"},{"id":"A377","pred":"chebi_id","subj":"T377","obj":"http://purl.obolibrary.org/obo/CHEBI_50667"},{"id":"A378","pred":"chebi_id","subj":"T378","obj":"http://purl.obolibrary.org/obo/CHEBI_16796"},{"id":"A379","pred":"chebi_id","subj":"T379","obj":"http://purl.obolibrary.org/obo/CHEBI_16796"}],"text":"As shown in Fig. 5a, targets of both mercaptopurine and melatonin showed strong network proximity with HCoV-associated host proteins in the human interactome network. Recent in vitro and in vivo studies identified mercaptopurine as a selective inhibitor of both SARS-CoV and MERS-CoV by targeting papain-like protease53,54. Melatonin was reported in potential antiviral infection via its anti-inflammatory and antioxidant effects58–62. Melatonin indirectly regulates ACE2 expression, a key entry receptor involved in viral infection of HCoVs, including 2019-nCoV/SARS-CoV-2 (ref. 33). Specifically, melatonin was reported to inhibit calmodulin and calmodulin interacts with ACE2 by inhibiting shedding of its ectodomain, a key infectious process of SARS-CoV72,73. JUN, also known as c-Jun, is a key host protein involving in HCoV infectious bronchitis virus74. As shown in Fig. 6d, mercaptopurine and melatonin may synergistically block c-Jun signaling by targeting multiple cellular targets. In summary, combination of mercaptopurine and melatonin may offer a potential combination therapy for 2019-nCoV/SARS-CoV-2 by synergistically targeting papain-like protease, ACE2, c-Jun signaling, and anti-inflammatory pathways (Fig. 6d). However, further experimental observations on ACE2 pathways by melatonin in 2019-nCoV/SARS-CoV-2 are highly warranted."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T52","span":{"begin":517,"end":532},"obj":"http://purl.obolibrary.org/obo/GO_0016032"},{"id":"T53","span":{"begin":943,"end":952},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T54","span":{"begin":1179,"end":1188},"obj":"http://purl.obolibrary.org/obo/GO_0023052"}],"text":"As shown in Fig. 5a, targets of both mercaptopurine and melatonin showed strong network proximity with HCoV-associated host proteins in the human interactome network. Recent in vitro and in vivo studies identified mercaptopurine as a selective inhibitor of both SARS-CoV and MERS-CoV by targeting papain-like protease53,54. Melatonin was reported in potential antiviral infection via its anti-inflammatory and antioxidant effects58–62. Melatonin indirectly regulates ACE2 expression, a key entry receptor involved in viral infection of HCoVs, including 2019-nCoV/SARS-CoV-2 (ref. 33). Specifically, melatonin was reported to inhibit calmodulin and calmodulin interacts with ACE2 by inhibiting shedding of its ectodomain, a key infectious process of SARS-CoV72,73. JUN, also known as c-Jun, is a key host protein involving in HCoV infectious bronchitis virus74. As shown in Fig. 6d, mercaptopurine and melatonin may synergistically block c-Jun signaling by targeting multiple cellular targets. In summary, combination of mercaptopurine and melatonin may offer a potential combination therapy for 2019-nCoV/SARS-CoV-2 by synergistically targeting papain-like protease, ACE2, c-Jun signaling, and anti-inflammatory pathways (Fig. 6d). However, further experimental observations on ACE2 pathways by melatonin in 2019-nCoV/SARS-CoV-2 are highly warranted."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T24","span":{"begin":841,"end":851},"obj":"Phenotype"}],"attributes":[{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0012387"}],"text":"As shown in Fig. 5a, targets of both mercaptopurine and melatonin showed strong network proximity with HCoV-associated host proteins in the human interactome network. Recent in vitro and in vivo studies identified mercaptopurine as a selective inhibitor of both SARS-CoV and MERS-CoV by targeting papain-like protease53,54. Melatonin was reported in potential antiviral infection via its anti-inflammatory and antioxidant effects58–62. Melatonin indirectly regulates ACE2 expression, a key entry receptor involved in viral infection of HCoVs, including 2019-nCoV/SARS-CoV-2 (ref. 33). Specifically, melatonin was reported to inhibit calmodulin and calmodulin interacts with ACE2 by inhibiting shedding of its ectodomain, a key infectious process of SARS-CoV72,73. JUN, also known as c-Jun, is a key host protein involving in HCoV infectious bronchitis virus74. As shown in Fig. 6d, mercaptopurine and melatonin may synergistically block c-Jun signaling by targeting multiple cellular targets. In summary, combination of mercaptopurine and melatonin may offer a potential combination therapy for 2019-nCoV/SARS-CoV-2 by synergistically targeting papain-like protease, ACE2, c-Jun signaling, and anti-inflammatory pathways (Fig. 6d). However, further experimental observations on ACE2 pathways by melatonin in 2019-nCoV/SARS-CoV-2 are highly warranted."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T193","span":{"begin":0,"end":166},"obj":"Sentence"},{"id":"T194","span":{"begin":167,"end":323},"obj":"Sentence"},{"id":"T195","span":{"begin":324,"end":435},"obj":"Sentence"},{"id":"T196","span":{"begin":436,"end":579},"obj":"Sentence"},{"id":"T197","span":{"begin":580,"end":584},"obj":"Sentence"},{"id":"T198","span":{"begin":585,"end":763},"obj":"Sentence"},{"id":"T199","span":{"begin":764,"end":860},"obj":"Sentence"},{"id":"T200","span":{"begin":861,"end":992},"obj":"Sentence"},{"id":"T201","span":{"begin":993,"end":1231},"obj":"Sentence"},{"id":"T202","span":{"begin":1232,"end":1350},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"As shown in Fig. 5a, targets of both mercaptopurine and melatonin showed strong network proximity with HCoV-associated host proteins in the human interactome network. Recent in vitro and in vivo studies identified mercaptopurine as a selective inhibitor of both SARS-CoV and MERS-CoV by targeting papain-like protease53,54. Melatonin was reported in potential antiviral infection via its anti-inflammatory and antioxidant effects58–62. Melatonin indirectly regulates ACE2 expression, a key entry receptor involved in viral infection of HCoVs, including 2019-nCoV/SARS-CoV-2 (ref. 33). Specifically, melatonin was reported to inhibit calmodulin and calmodulin interacts with ACE2 by inhibiting shedding of its ectodomain, a key infectious process of SARS-CoV72,73. JUN, also known as c-Jun, is a key host protein involving in HCoV infectious bronchitis virus74. As shown in Fig. 6d, mercaptopurine and melatonin may synergistically block c-Jun signaling by targeting multiple cellular targets. In summary, combination of mercaptopurine and melatonin may offer a potential combination therapy for 2019-nCoV/SARS-CoV-2 by synergistically targeting papain-like protease, ACE2, c-Jun signaling, and anti-inflammatory pathways (Fig. 6d). However, further experimental observations on ACE2 pathways by melatonin in 2019-nCoV/SARS-CoV-2 are highly warranted."}

2_test

{"project":"2_test","denotations":[{"id":"32194980-19374142-19614228","span":{"begin":317,"end":319},"obj":"19374142"},{"id":"32194980-25542975-19614229","span":{"begin":320,"end":322},"obj":"25542975"},{"id":"32194980-24090288-19614230","span":{"begin":429,"end":431},"obj":"24090288"},{"id":"32194980-22264213-19614230","span":{"begin":429,"end":431},"obj":"22264213"},{"id":"32194980-25262626-19614230","span":{"begin":429,"end":431},"obj":"25262626"},{"id":"32194980-17198536-19614230","span":{"begin":429,"end":431},"obj":"17198536"},{"id":"32194980-22998574-19614230","span":{"begin":429,"end":431},"obj":"22998574"},{"id":"32194980-32015507-19614231","span":{"begin":580,"end":582},"obj":"32015507"},{"id":"32194980-18070603-19614232","span":{"begin":757,"end":759},"obj":"18070603"},{"id":"32194980-12071468-19614233","span":{"begin":760,"end":762},"obj":"12071468"},{"id":"32194980-29238080-19614234","span":{"begin":857,"end":859},"obj":"29238080"}],"text":"As shown in Fig. 5a, targets of both mercaptopurine and melatonin showed strong network proximity with HCoV-associated host proteins in the human interactome network. Recent in vitro and in vivo studies identified mercaptopurine as a selective inhibitor of both SARS-CoV and MERS-CoV by targeting papain-like protease53,54. Melatonin was reported in potential antiviral infection via its anti-inflammatory and antioxidant effects58–62. Melatonin indirectly regulates ACE2 expression, a key entry receptor involved in viral infection of HCoVs, including 2019-nCoV/SARS-CoV-2 (ref. 33). Specifically, melatonin was reported to inhibit calmodulin and calmodulin interacts with ACE2 by inhibiting shedding of its ectodomain, a key infectious process of SARS-CoV72,73. JUN, also known as c-Jun, is a key host protein involving in HCoV infectious bronchitis virus74. As shown in Fig. 6d, mercaptopurine and melatonin may synergistically block c-Jun signaling by targeting multiple cellular targets. In summary, combination of mercaptopurine and melatonin may offer a potential combination therapy for 2019-nCoV/SARS-CoV-2 by synergistically targeting papain-like protease, ACE2, c-Jun signaling, and anti-inflammatory pathways (Fig. 6d). However, further experimental observations on ACE2 pathways by melatonin in 2019-nCoV/SARS-CoV-2 are highly warranted."}

PMC:7073332 / 31237-32587 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7073332 / 31237-32587 JSON TXT